IL1B and chronic obstructive pulmonary disease: The effects of IL-1β contribute to the regulation of local inflammatory and repair responses, and its dysregulation has been implicated in numerous lung physiopathological conditions, including pulmonary fibrosis, asbestosis, chronic obstructive pulmonary disease (COPD), emphysema, severe cases of COVID-19, and other types of acute lung injury [23,24,25,26,27], which have drawn the interest of the pharmaceutical industry [23].